Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880040 | 0.93 | SCN9A (0.48) | SCN9ASYKPTGER4KDM4ESMN1; SMN2 | |
| SCHEMBL6878697 | 0.90 | SCN9A (0.45) | SCN9ASYKPTGER4KDM4ESMN1; SMN2 | |
| SCHEMBL6878696 | 0.77 | RAD52 (0.42) | SCN9ASYKRAD52MEN1KMT2A | |
| SCHEMBL6879926 | 0.77 | SELP (0.44) | SYKKDM4ERAD52P2RX3P2RX2 | |
| SCHEMBL6878439 | 0.75 | SYK (0.43) | SYKP2RX3P2RX2 | |
| SCHEMBL6878766 | 0.74 | KDM4E (0.46) | PTGER4KDM4ESMN1; SMN2MEN1KMT2A | |
| Dimethylaminoethanol SCHEMBL6877129 | 0.71 | KDM4E (0.43) | PTGER4KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL5800535 | 0.70 | TACR1 (0.44) | SCN9ASYK | |
| SCHEMBL6871949 | 0.69 | SYK (0.39) | SCN9ASYK | |
| SCHEMBL6862226 | 0.69 | SCN9A (0.43) | SCN9ASYKKDM4ESMN1; SMN2NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787539-B2 | HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| US-20020099207-A1 | 2,4,5,-trisubstituted pyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099207-A1 | 2,4,5,-trisubstituted pyrimidine derivatives | TACR1, TACR2, P2RY2 | SCN9A 1166/4885SYK 872/4885PTGER4 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.